At GNS, we reveal the hidden biological circuitry of disease to create the world’s most accurate “virtual patients” and “digital twins”. These “virtual patients” are powered by the recent explosive growth of multi-omic and clinical patient data and our patented Causal AI and Simulation technology REFS™.
Gemini Virtual Patients enable the accurate simulation of gene and protein knockdowns at the individual patient level across “virtual patient cohorts” to discover and validate novel drug targets.
Gemini Virtual Patients also enable the simulation of disease progression and drug response at the individual patient level across “virtual patient cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.
Meet Gemini
Virtual Patient
Gemini – Virtual Patient is fueled by integrated multi-omic and clinical patient data in specific diseases from a rapidly growing array of world class partners and the patented causal AI and simulation technology, REFS™. These “virtual patients” link patient characteristics to drug treatments to the “revealed” complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the world’s most accurate simulation of disease progression and drug response at an individual patient level across “virtual patient cohorts.” Gemini Virtual Patients have been launched in multiple myeloma, prostate cancer, Alzheimer, and Parkinson’s, with several more in development.
Collaborate with GNS to Discover and Develop
Innovative Therapeutics
Gemini Virtual Patient
Data Partners
Gemini Virtual Patient
Biopharma Partners
